Opaleye Management’s Neurocrine Biosciences NBIX Stock Holding History

Opaleye Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-55,000	Closed	-$3.11M	–	57
2015 Q4	$3.11M	Sell	55,000 -70,000	-56%	-$3.56M	1.3%	32
2015 Q3	$4.97M	Sell	125,000 -20,000	-14%	-$967K	2.45%	19
2015 Q2	$6.92M	Hold	145,000	–	–	2.76%	14
2015 Q1	$5.76M	Buy	145,000 +100,000	+222%	+$3.58M	2.67%	17
2014 Q4	$1M	Buy	+45,000	New	+$853K	0.51%	34

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Opaleye Management's NBIX Position: Q1 2016 in Review

Opaleye Management sold out of Neurocrine Biosciences (NBIX) in Q1 2016, closing a stake of 55,000 shares — an estimated $3.11M sold.

Opaleye Management first reported a position in NBIX in Q4 2014 and held it in 5 quarters. The position peaked at $6.92M in Q2 2015. 213 funds tracked by Wall St. Rank hold NBIX as of Q1 2016.

Opaleye Management reported no remaining Neurocrine Biosciences position as of Q1 2016 after selling out during the quarter.
Opaleye Management sold 55,000 Neurocrine Biosciences shares in Q1 2016, an estimated $3.11M.
Opaleye Management first reported a position in Neurocrine Biosciences in Q4 2014 and held it in 5 quarters.
Opaleye Management's Neurocrine Biosciences position peaked at $6.92M in Q2 2015.
213 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2016.

Based on Opaleye Management's 13F filing for Q1 2016, filed 16 May 2016.